person · Reporting owner
JOHNSON KENNETH ERLAND
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| XERIS PHARMACEUTICALS INCXERS · Entity 134906 | See Remarks | October 05, 2021 | October 05, 2021 |
| Xeris Biopharma Holdings, Inc.XERS · Entity 4670 | See Remarks | January 31, 2025 | February 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
XERIS PHARMACEUTICALS INC
Report date October 05, 2021 · Filed October 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,333 |
Reported balance
After 2021-10-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-10-05 · Disposition to issuer · Disposed 11,250 · Balance 78,333 F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-10-05 · Disposition to issuer · Disposed 78,333 · Balance 0 F3: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2027-02-04 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-10-05 · Disposition to issuer · Disposed 33,686 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5: These options are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2027-06-12 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-10-05 · Disposition to issuer · Disposed 5,280 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5: These options are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.93 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-10-05 · Disposition to issuer · Disposed 39,633 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. F8: These options are early exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2028-10-04 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-10-05 · Disposition to issuer · Disposed 21,401 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2029-01-31 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-10-05 · Disposition to issuer · Disposed 32,500 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2030-08-14 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-10-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F7: 50% of these options shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction").
F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax.
F3: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time.
F4: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option.
F5: These options are fully vested as of the date hereof.
F6: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
F7: 50% of these options shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date.
F8: These options are early exercisable.
Xeris Biopharma Holdings, Inc.
Report date January 31, 2025 · Filed February 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 320,446 |
Ending reported balance
After 2025-01-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-01-31 · Tax withholding · Disposed 15,476 · Balance 346,288 F1: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. Row 2 · 2025-01-31 · Tax withholding · Disposed 25,842 · Balance 320,446 F1: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2025 Filed Feb 3, 2025 19:39 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 25,842 | $3.56 | $91,997.52 |
DisclosureSEC source: 0001867096-25-000023 · wk-form4_1738629545.xml · nonDerivative · entry 2 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,446 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 19:39 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 15,476 | $3.56 | $55,094.56 |
DisclosureSEC source: 0001867096-25-000023 · wk-form4_1738629545.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,288 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 16:42 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 12,401 | $3.61 | $44,767.61 |
DisclosureSEC source: 0001867096-25-000013 · wk-form4_1736286143.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,764 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of Restricted Stock Units vested as of January 3, 2025. F2 · balance_after: Includes 1,129 shares acquired on December 31, 2024 under the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, as amended. Read SEC document |
| January 31, 2024 Filed Jan 31, 2024 17:04 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-24-000016 · wk-form4_1706738685.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,860 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. F2 · balance_after: These shares include 2,077 shares that were purchased on June 30, 2023 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| January 31, 2024 Filed Aug 9, 2024 16:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 15,131 | $2.46 | $37,222.26 |
DisclosureSEC source: 0001867096-24-000169 · wk-form4_1723234020.xml · nonDerivative · entry 8 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,036 F1 · date: This transaction is being reported late due to administrative oversight. F10 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024. Read SEC document |
| January 29, 2024 Filed Aug 9, 2024 16:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 10,747 | $2.66 | $28,587.02 |
DisclosureSEC source: 0001867096-24-000169 · wk-form4_1723234020.xml · nonDerivative · entry 7 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,167 F1 · date: This transaction is being reported late due to administrative oversight. F9 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024. Read SEC document |
| January 03, 2024 Filed Aug 9, 2024 16:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 12,400 | $2.24 | $27,776.00 |
DisclosureSEC source: 0001867096-24-000169 · wk-form4_1723234020.xml · nonDerivative · entry 6 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 398,914 F1 · date: This transaction is being reported late due to administrative oversight. F8 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024. Read SEC document |
| January 31, 2023 Filed Feb 1, 2023 16:12 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-23-000019 · wf-form4_167528590383194.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,783 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. F2 · balance_after: These shares include 1,460 shares that were purchased on June 30, 2022 and 1,700 shares that were purchased on December 31, 2022 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| January 31, 2023 Filed Aug 9, 2024 16:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 3,393 | $1.24 | $4,207.32 |
DisclosureSEC source: 0001867096-24-000169 · wk-form4_1723234020.xml · nonDerivative · entry 5 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,314 F1 · date: This transaction is being reported late due to administrative oversight. F7 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023. Read SEC document |
| January 29, 2023 Filed Aug 9, 2024 16:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 11,029 | $1.26 | $13,896.54 |
DisclosureSEC source: 0001867096-24-000169 · wk-form4_1723234020.xml · nonDerivative · entry 4 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,707 F1 · date: This transaction is being reported late due to administrative oversight. F6 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023. Read SEC document |
| January 03, 2023 Filed Aug 9, 2024 16:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 12,400 | $1.12 | $13,888.00 |
DisclosureSEC source: 0001867096-24-000169 · wk-form4_1723234020.xml · nonDerivative · entry 3 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,736 F1 · date: This transaction is being reported late due to administrative oversight. F5 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023. Read SEC document |
| January 31, 2022 Filed Aug 9, 2024 16:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 2,307 | $2.11 | $4,867.77 |
DisclosureSEC source: 0001867096-24-000169 · wk-form4_1723234020.xml · nonDerivative · entry 2 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,136 F1 · date: This transaction is being reported late due to administrative oversight. F4 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022. Read SEC document |
| January 29, 2022 Filed Aug 9, 2024 16:07 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 7,497 | $2.11 | $15,818.67 |
DisclosureSEC source: 0001867096-24-000169 · wk-form4_1723234020.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,443 F1 · date: This transaction is being reported late due to administrative oversight. F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022. F3 · balance_after: These shares include 1,080 shares that were purchased on June 30, 2024 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 18:17 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-22-000010 · wf-form4_164142460391215.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,865 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. F2 · balance_after: These shares include 534 shares that were purchased on June 30, 2021 and 748 shares that were purchased on December 31, 2021 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:33 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $3.94 | Not disclosed |
DisclosureSEC source: 0000899243-21-039246 · doc4.xml · derivative · entry 8 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2030-08-14 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F7 · derivative.exercise_date: 50% of these options shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:33 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 32,500 | Not disclosed Strike: $13.88 | Not disclosed |
DisclosureSEC source: 0000899243-21-039246 · doc4.xml · derivative · entry 7 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,500 shares Expires 2029-01-31 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:33 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,401 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-039246 · doc4.xml · derivative · entry 6 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,401 shares Expires 2028-10-04 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:33 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 39,633 | Not disclosed Strike: $5.93 | Not disclosed |
DisclosureSEC source: 0000899243-21-039246 · doc4.xml · derivative · entry 5 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,633 shares Expires 2028-01-31 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. F8 · derivative.exercise_date: These options are early exercisable. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:33 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,280 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039246 · doc4.xml · derivative · entry 4 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,280 shares Expires 2027-06-12 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:33 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 33,686 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039246 · doc4.xml · derivative · entry 3 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,686 shares Expires 2027-02-04 F4 · kind: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:33 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerCommon Stock | 78,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039246 · doc4.xml · nonDerivative · entry 2 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · security: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. F3 · kind: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. F3 · price: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 17:33 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | Disposition to issuerCommon Stock | 11,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039246 · doc4.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,333 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · kind: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $3.94 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 8 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-08-14 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F7 · derivative.exercise_date: 50% of these options shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 32,500 | Not disclosed Strike: $13.88 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 7 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2029-01-31 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 21,401 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 6 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,401 Underlying: Common Stock · 21,401 shares Expires 2028-10-04 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 39,633 | Not disclosed Strike: $5.93 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 5 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,633 Underlying: Common Stock · 39,633 shares Expires 2028-01-31 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 5,280 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 4 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,280 Underlying: Common Stock · 5,280 shares Expires 2027-06-12 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 33,686 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 3 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,686 Underlying: Common Stock · 33,686 shares Expires 2027-02-04 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 78,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · nonDerivative · entry 2 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,583 F3 · security: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · kind: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · price: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 11,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · kind: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 16:12 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001346302-21-000010 · wf-form4_161221395526952.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,890 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on January 29, 2022. Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 16:35 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0000899243-20-022591 · doc4.xml · derivative · entry 2 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-08-14 F1 · derivative.exercise_date: 50% of these shares shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date. Read SEC document |
| June 30, 2020 Filed Jul 15, 2020 16:52 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | GrantCommon Stock | 775 | $2.26 | $1,751.50 |
DisclosureSEC source: 0000899243-20-019177 · doc4.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,890 F1 · security: These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from January 1, 2020 through June 30, 2020. F2 · shares: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2020. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 16:59 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | PurchaseCommon Stock | 2,410 | $4.15 | $10,001.50 |
DisclosureSEC source: 0000899243-20-004907 · doc4.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,115 F1 · kind: Represents shares purchased in an underwritten public offering of the Issuer at the public offering price of $4.15 per share. Read SEC document |
| January 31, 2020 Filed Mar 2, 2020 16:56 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006521 · doc4.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,115 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on January 31, 2021. Read SEC document |
| December 31, 2019 Filed Jan 6, 2020 18:10 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | GrantCommon Stock | 286 | $5.99 | $1,713.14 |
DisclosureSEC source: 0000899243-20-000615 · doc4.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,705 F1 · security: These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from July 1, 2019 through December 31, 2019. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on December 31, 2019. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 16:57 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | GrantCommon Stock | 174 | $9.72 | $1,691.28 |
DisclosureSEC source: 0000899243-19-019201 · doc4.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,419 F1 · security: These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from January 1, 2019 through June 30, 2019. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 28, 2019. Read SEC document |
| February 19, 2019 Filed Feb 25, 2019 17:38 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | PurchaseCommon Stock | 1,000 | $10.00 | $10,000.00 |
DisclosureSEC source: 0000899243-19-004728 · doc4.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,245 F1 · kind: Mr. Johnson purchased shares of common stock from the underwriters in a public offering pursuant to the registrant's Registration Statement on Form S-1 (File No. 333-229665, completed on February 19, 2019). The shares of common stock were purchased at the public offering price. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 16:40 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | GrantStock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0000899243-19-002326 · doc4.xml · derivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2029-01-31 F1 · derivative.exercise_date: 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:35 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | ConversionSeries C Preferred Stock · Derivative | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018500 · doc4.xml · derivative · entry 2 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,245 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:35 UTC | XERIS PHARMACEUTICALS INC XERS · Entity 134906 | ConversionCommon Stock | 2,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018500 · doc4.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.